Evaluation of clinical and genetic indicators for the early response to intravitreal ranibizumab in exudative age-related macular degeneration

Pharmacogenomics

Volumn 15, Issue 6, 2014, Pages 833-843

  Matsumiya, Wataru ^a   Honda, Shigeru ^a   Yanagisawa, Suiho ^a   Miki, Akiko ^a   Nagai, Takayuki ^a   Tsukahara, Yasutomo ^a  

^a KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

3 months results; age related macular degeneration; age related maculopathy susceptibility 2; anatomical outcome; complement factor H; ranibizumab; single nucleotide polymorphism

Indexed keywords

RANIBIZUMAB; ARMS2 PROTEIN, HUMAN; COMPLEMENT FACTOR H; MONOCLONAL ANTIBODY; PROTEIN;

AGED; ARMS2 GENE; ARTICLE; CENTRAL RETINAL THICKNESS; CFH GENE; CONTROLLED STUDY; FEMALE; GENE; GENE LOCUS; GENETIC ASSOCIATION; GENETIC VARIABILITY; HUMAN; JAPANESE (PEOPLE); MAJOR CLINICAL STUDY; MALE; OPHTHALMOSCOPY; OPTICAL COHERENCE TOMOGRAPHY; POLYPOIDAL CHOROIDAL VASCULOPATHY; RETINA MACULA AGE RELATED DEGENERATION; RETROSPECTIVE STUDY; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT RESPONSE; ASIAN CONTINENTAL ANCESTRY GROUP; DRUG EFFECTS; GENETICS; INTRAVITREAL DRUG ADMINISTRATION; MACULAR DEGENERATION; PROCEDURES; RETINA;

AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ASIAN CONTINENTAL ANCESTRY GROUP; COMPLEMENT FACTOR H; FEMALE; HUMANS; INTRAVITREAL INJECTIONS; MACULAR DEGENERATION; MALE; POLYMORPHISM, SINGLE NUCLEOTIDE; PROTEINS; RETINA; RETROSPECTIVE STUDIES;

EID: 84901984256     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.14.51     Document Type: Article

References (34)

1. Hernandez-Pastor LJ, Ortega A, Garcia-Layana A, Giraldez J. Ranibizumab for neovascular age-related macular degeneration. Am. J. Health Syst. Pharm. 65(19), 1805-1814 (2008).
2. Morris B, Imrie F, Armbrecht AM, Dhillon B. Age-related macular degeneration and recent developments: new hope for old eyes? Postgrad. Med. J. 83(979), 301-307 (2007).
3. Mitchell P, Korobelnik JF, Lanzetta P et al. Ranibizumab (Lucentis) in neovascular age-related macular degeneration: evidence from clinical trials. Br. J. Ophthalmol. 94(1), 2-13 (2010).
4. Fung AE, Lalwani GA, Rosenfeld PJ et al. An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration. Am. J. Ophthalmol. 143(4), 566-583 (2007).
5. CATT Research Group, Martin DF, Maguire MG et al. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N. Engl. J. Med. 364(20), 1897-1908 (2011).
6. Otsuji T, Nagai Y, Sho K et al. Initial non-responders to ranibizumab in the treatment of age-related macular degeneration (AMD). Clin. Ophthalmol. 7, 1487-1490 (2013).
7. Menghini M, Kloeckener-Gruissem B, Fleischhauer J et al. Impact of loading phase, initial response and CFH genotype on the long-term outcome of treatment for neovascular age-related macular degeneration. PLoS ONE 7(7), e42014 (2012).
8. Brown DM, Tuomi L, Shapiro H; Pier Study Group. Anatomical measures as predictors of visual outcomes in ranibizumab-treated eyes with neovascular age-related macular degeneration. Retina 33(1), 23-34 (2013).
9. Matsumiya W, Honda S, Bessho H, Kusuhara S, Tsukahara Y, Negi A. Early responses to intravitreal ranibizumab in typical neovascular age-related macular degeneration and polypoidal choroidal vasculopathy. J. Ophthalmol. 2011, 742020 (2011).
10. Matsumiya W, Honda S, Kusuhara S, Tsukahara Y, Negi A. Effectiveness of intravitreal ranibizumab in exudative age-related macular degeneration (AMD): comparison between typical neovascular AMD and polypoidal choroidal vasculopathy over a 1 year follow-up. BMC Ophthalmol. 13, 10 (2013).
11. Schmidt-Erfurth UM, Richard G, Augustin A et al. Guidance for the treatment of neovascular age-related macular degeneration. Acta Ophthalmol. Scand. 85(5), 486-494 (2007).
12. Ip MS, Scott IU, Brown GC et al. Anti-vascular endothelial growth factor pharmacotherapy for age-related macular degeneration: a report by the American academy of ophthalmology. Ophthalmology 115(10), 1837-1846 (2008).
13. Rosenfeld PJ, Brown DM, Heier JS et al. Ranibizumab for neovascular age-related macular degeneration. N. Engl. J. Med. 355(14), 1419-1431 (2006).
14. Brown DM, Michels M, Kaiser PK et al. Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: two-year results of the ANCHOR study. Ophthalmology 116(1), 57-65 (2009).
15. Wolf S, Holz FG, Korobelnik JF et al. Outcomes following three-line vision loss during treatment of neovascular age-related macular degeneration: subgroup analyses from MARINA and ANCHOR. Br. J. Ophthalmol. 95(12), 1713-1718 (2011).
16. Chen H, Yu KD, Xu GZ. Association between variant Y402H in age-related macular degeneration (AMD) susceptibility gene CFH and treatment response of AMD: a meta-analysis. PLoS ONE 7(8), e42464 (2012).
17. Francis PJ. The influence of genetics on response to treatment with ranibizumab (Lucentis) for age-related macular degeneration: the Lucentis Genotype Study (an American Ophthalmological Society thesis). Trans. Am. Ophthalmol. Soc. 109, 115-156 (2011).
18. Orlin A, Hadley D, Chang W et al. Association between high-risk disease loci and response to anti-vascular endothelial growth factor treatment for wet age-related macular degeneration. Retina 32(1), 4-9 (2012).
19. Kloeckener-Gruissem B, Barthelmes D, Labs S et al. Genetic association with response to intravitreal ranibizumab in patients with neovascular AMD. Invest. Ophthalmol. Vis. Sci. 52(7), 4694-4702 (2011).
20. Yamashiro K, Tomita K, Tsujikawa A et al. Factors associated with the response of age-related macular degeneration to intravitreal ranibizumab treatment. Am. J. Ophthalmol. 154(1), 125-136 (2012).
21. McKibbin M, Ali M, Bansal S et al. CFH, VEGF and HTRA1 promoter genotype may influence the response to intravitreal ranibizumab therapy for neovascular age-related macular degeneration. Br. J. Ophthalmol. 96(2), 208-212 (2012).
22. Lee AY, Raya AK, Kymes SM, Shiels A, Brantley MA. Pharmacogenetics of complement factor H (Y402H) and treatment of exudative age-related macular degeneration with ranibizumab. Br. J. Ophthalmol. 93(5), 610-613 (2009).
23. Agosta E, Lazzeri S, Orlandi P et al. Pharmacogenetics of antiangiogenic and antineovascular therapies of age-related macular degeneration. Pharmacogenomics 13(9), 1037-1053 (2012).
24. Smailhodzic D, Muether PS, Chen J et al. Cumulative effect of risk alleles in CFH, ARMS2, and VEGFA on the response to ranibizumab treatment in age-related macular degeneration. Ophthalmology 119(11), 2304-2311 (2012).
25. Abedi F, Wickremasinghe S, Richardson AJ et al. Variants in the VEGFA gene and treatment outcome after anti-VEGF treatment for neovascular age-related macular degeneration. Ophthalmology 120(1), 115-121 (2013).
26. Chang W, Noh DH, Sagong M, Kim IT. Pharmacogenetic association with early response to intravitreal ranibizumab for age-related macular degeneration in a Korean population. Mol. Vis. 19, 702-709 (2013).
27. Lazzeri S, Figus M, Orlandi P et al. VEGF-A polymorphisms predict short-term functional response to intravitreal ranibizumab in exudative age-related macular degeneration. Pharmacogenomics 14(6), 623-630 (2013).
28. Shaw PX, Zhang L, Zhang M et al. Complement factor H genotypes impact risk of age-related macular degeneration by interaction with oxidized phospholipids. Proc. Natl Acad. Sci. USA 109(34), 13757-13762 (2012).
29. Kondo N, Bessho H, Honda S, Negi A. Complement factor H Y402H variant and risk of age-related macular degeneration in Asians: a systematic review and meta-analysis. Ophthalmology 118(2), 339-344 (2011).
30. Tortajada A, Montes T, Martínez-Barricarte R, Morgan BP, Harris CL, de Córdoba SR. The disease-protective complement factor H allotypic variant Ile62 shows increased binding affinity for C3b and enhanced cofactor activity. Hum. Mol. Genet. 18(18), 3452-3461 (2009).
31. Appel GB, Cook HT, Hageman G et al. Membranoproliferative glomerulonephritis type II (dense deposit disease): an update. J. Am. Soc. Nephrol. 16(5), 1392-1403 (2005).
32. Johnson PT, Betts KE, Radeke MJ, Hageman GS, Anderson DH, Johnson LV. Individuals homozygous for the age-related macular degeneration risk-conferring variant of complement factor H have elevated levels of CRP in the choroid. Proc. Natl Acad. Sci. USA 103(46), 17456-17461 (2006).
33. Bessho H, Honda S, Kondo N, Negi A. The association of ARMS2 polymorphisms with phenotype in typical neovascular age-related macular degeneration and polypoidal choroidal vasculopathy. Mol. Vis. 17, 977-982 (2011).
34. Brantley MA, Fang AM, King JM, Tewari A, Kymes SM, Shiels A. Association of complement factor H and LOC387715 genotypes with response of exudative age-related macular degeneration to intravitreal bevacizumab. Ophthalmology 114(12), 2168-2173 (2007).